Background: Mesenchymal stem cells (MSC) have garnered considerable attention in plastic surgery. Via proliferation/differentiation or the elaboration of paracrine factors, MSC and their adipose-derived stem cell counterparts (ADSC) have been suggested to stimulate cutaneous wound healing. Previous reports have been limited by a lack of appropriate controls and the lack of a clinically-relevant context or ability to extrapolate to human wound healing. Objectives: The authors qualitatively and quantitatively evaluate the ability of ADSC to improve wound healing in an ischemic variant of their wellestablished rabbit ear wound model. Methods: To incorporate ischemia, a major pathophysiologic factor in human chronic wounds, into our model, two of the three main arteries to the rabbit ear were ligated before wounding. Green fluorescent protein (GFP)-labeled ADSC or rabbit dermal fibroblasts (RDF) were then applied to wounds and histologic parameters of healing quantified. Results: At Postoperative Day (POD) 1, both cell types were present in a uniform distribution across wounds and positive for the proliferation marker Ki-67. By POD 7 and continuing through POD 10, ADSC and RDF contributed similarly to the accumulation of stratified "neogranulation" across the wound bed. No statistically-significant differences were observed between ADSC and RDF in terms of this positive effect on granulation (P = .2-.3 for comparison of mean granulation tissue gaps and areas). Conclusions: ADSC and RDF can be delivered topically to wounds, resulting in a high level of engraftment in the ischemic background. Cellular wound therapy holds promise for chronic wound healing as well as other antiscarring therapies, but further studies are warranted before full clinical translation.
In the surgical and medical fields alike, we currently stand at the dawn of an exciting new era in therapeutics thanks to the isolation and characterization of stem cells. "Adult" stem cells are now known to reside in a wide variety of organs and thought to act as a source of replenishment for injured tissues. 1, 2 Much to researchers' initial surprise and delight, a number of different types of adult stem cells possess the ability not only to self-renew and differentiate into committed daughter cells of their respective tissues but also to transdifferentiate into cells of other tissue types given the right cues. 3 Adult mesenchymal stem cells (MSC), for example, can give rise to cells that form bone, cartilage, muscle, fat, and other connective tissues. 4 These demonstrations, together with the finding that adipose tissue harbors vast numbers of similarly-acting multipotent mesenchymal progenitors termed adipose-derived stem cells (ADSC), [5] [6] [7] have sparked considerable interest among plastic surgeons in employing stem cells to aid wound repair. Proposed applications run the gamut from Equivalent Effects of Topically-Delivered Adipose-Derived Stem Cells and Dermal Fibroblasts in the Ischemic Rabbit Ear Model for Chronic Wounds stimulation of closure of chronic, difficult-to-heal wounds, to hypertrophic scar prevention and/or treatment, to soft tissue augmentation in the form of natural filler. [8] [9] [10] Patient safety must take precedence, however, and the time is clearly ripe for rigorous basic scientific and translational research studies before such clinical uses of stem cells become commonplace. An abundance of unsubstantiated marketing claims prompted the recent joint position statement of the American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS) on stem cells, 11, 12 which further emboldens the call for careful preclinical analysis of stem cells and ADSC in particular.
With regard to cutaneous wound healing, attention has shifted in the past decade away from single-agent growth factor therapies and toward the application of living cellular constructs. In patients with acute burns, cultured epithelial autografts consisting of ex vivo expanded keratinocytes have been successfully delivered to wounds in an aerosol formulation and have been shown to accelerate reepithelialization, improve time to total wound cover, reduce hospital lengths of stay, and improve overall survival. 13, 14 For chronic wounds such as venous stasis and diabetic ulcers, several forms of bioengineered skin are now readily available and have demonstrated promise in achieving definitive healing. 15, 16 These methods do have some shortcomings, however. Cultured keratinocytes appear to provide reliable epithelial cover in the short term but, because of a lack of dermal support in many deep burn wounds, may not be ideal for durable resurfacing of wounds in the long term.
14 Moreover, bioengineered skin for the treatment of nonhealing ulcers has been shown in some cases to induce a foreign body granulomatous response and therefore may be more suitable for temporary coverage rather than long-term definitive integration. [17] [18] [19] Finally, despite the development and current market availability of a variety of skin substitutes, some 50% of patients with chronic wounds resistant to conventional wound care therapies still fail to completely heal. 16 The next generation in biotherapeutics for cutaneous wound healing will almost certainly center on agents that, by virtue of their complete integration into host tissues, will not only modulate the formation of scar but drive their respective microenvironments toward more regenerative phenotypes. An early and evolving literature of MSC in cutaneous wounds suggest that these cells may be uniquely poised to fulfill this role. In rabbit 20 and rat 21 incisional wounds, MSC injected intravenously or delivered directly to wounds appear to inhibit excessive scar formation and increase the bursting strength of treated wounds as assessed by tensiometry. In mouse excisional wound models, MSC injected intravenously 22 or applied directly to wounds [23] [24] [25] [26] can significantly accelerate the time to wound closure. MSC may stimulate wound repair through proliferation/differentiation or paracrine "trophic effects."
2 Consistent with these roles, labeled MSC injected intravenously or delivered directly to wounds in mice have been shown to localize within or close to vascular structures and to express markers of endothelial cells or pericytes. [22] [23] [24] 27 Some reports have also indicated more direct incorporation of MSC into developing dermal appendages 23 or collagen-producing myofibroblasts. 28 In terms of trophic effects, media conditioned from MSC and ADSC are a rich source of vulnerary, angiogenic, and antioxidant factors 23, 25, 26, [28] [29] [30] and have been shown to promote the following: outgrowth of keratinocytes from rabbit dermal explants, 28 angiogenic tube formation among cultured endothelial cells, 23 and migration, proliferation, and upregulation of collagen production and antioxidant enzyme activity in cultured fibroblasts. 26, 29 The promise of MSC for cutaneous wound healing must be tempered by an understanding of several key limitations of the studies to date. First among these is a lack of appropriate controls in the majority of reports. The identity of the most appropriate and pertinent controls for trials of wound healing is certainly debatable. Nonetheless, fibroblasts-cells known to contribute to wound repair and already a component of many commercially available biotherapeutic products 15 -can be readily cultured and may serve as the best standard for comparison. The second major limitation of current studies is the lack of a suitable experimental system for extrapolation to human cutaneous wounds. Because almost all animals are looseskinned, their wounds tend to heal nearly entirely by contraction. This is in contrast to human wounds, particularly those on the leg, which heal almost entirely by reepithelialization and granulation and only minimally by contraction. 31 The third, and perhaps most significant, shortcoming of recent studies is the lack of a clinicallyrelevant context. The finding of accelerated wound closure in normal mice with MSC or ADSC application is of limited clinical import since healing in the absence of such treatments would proceed without any deficits. Greater clinical value would be achieved from data showing that MSC or ADSC can improve the defective healing seen in patients with chronic wounds such as venous stasis, diabetic, and pressure ulcers.
The objective of the present work was to qualitatively and quantitatively evaluate the ability of ADSC to improve wound healing in an ischemic variant of our well-established rabbit ear wound model. This system has the advantage that the underlying ear cartilage serves as a natural splint and prevents wound healing by contracture. As originally described in 1990, 32 the model can be easily adapted for ischemia, a key element in the pathogenesis of chronic wounds, by ligating two of the three main arteries to the rabbit ear. Finally, the system is ideal for side-byside comparison of experimental treatments with controls, which enables paired statistical analyses and eliminates the subject-to-subject variation that is often encountered in animal studies. In our experiments, rabbit dermal fibroblasts (RDF) were used as controls. It was our hope that this study would yield critical information regarding the in vivo behavior of ADSC and dermal fibroblasts prior to any consideration of the use of these cells in clinical wound healing or antiscarring approaches. with minor variations. Briefly, the inguinal fat pads were dissected and placed in sterile, prewarmed phosphatebuffered saline (PBS). Each fat pad yielded approximately 4 to 5 grams of tissue after removing evident blood vessels. One fat pad was taken for harvest, washed several times in PBS, minced manually to the consistency of applesauce, and digested in 250 U/mL type I collagenase in Ham's DMEM/F12 (Invitrogen, Carlsbad, CA) for one hour at 37°C in a shaking water bath. After digestion and inactivation of the collagenase, the mixture was filtered through a 100-µm sterile nylon mesh filter and spun at 1200 g for five minutes. The resultant pellet was washed with Ham's DMEM/F12, resuspended in 10 mL of red blood cell (RBC) lysis buffer, and allowed to sit at room temperature for 15 minutes. Following RBC lysis, the supernatant was removed and the pellet was washed twice with DMEM/F12 + 10% fetal bovine serum (FBS; Invitrogen) and plated in 10-cm plates in the same complete media. Cells were allowed to adhere for three hours, and the culture medium was then gently removed and replaced. Cells were typically confluent within three to four days. On average, 4 to 5 grams of fat pad tissue yielded 1 × 10 6 adherent cells, which suggests the presence of approximately 2.5 × 10 5 ADSC per gram of rabbit inguinal fat pad. ADSC were passaged four to seven times (P4-P7) before application to rabbit ear wounds. Multipotentiality was confirmed in vitro using chemical cocktails for adipogenesis, osteogenesis, and chrondrogenesis as previously described. 33 Wound treatments were performed in an allogeneic fashion, in that ADSC harvested and cultured from one New Zealand White rabbit were later applied to wounds of a different (yet genetically quite similar) New Zealand White rabbit. For RDF controls, an RDF cell line was obtained from ATCC (CRL-1414; ATCC, Manassas, Virginia). This cell line was selected in favor of primary RDF culture to ensure RDF homogeneity and minimize the presence of any cross-contaminating MSC or pericytes in the culture. RDF were maintained in DMEM containing 10% FBS (Invitrogen).
Lentiviral Green Fluorescent Protein Transduction of ADSC and RDF
To follow the in vivo fate of topically-delivered ADSC and RDF in the rabbit ear, cells were labeled with green fluorescent protein (GFP) via lentiviral transduction. A cytomegalovirus (CMV)-driven lentiviral construct was utilized (pLenti6/TR; Invitrogen). Briefly, cells were infected with multiplicity of infection (MOI) 2 of lentivirus in the presence of 6 µg/mL of polybrene. Transduced cells were then selected by treating cultures with 10 µg/mL blasticidin.
Due to the growth of a minor population of GFPnonexpressing cells in the presence of blasticidin, fluorescence-activated cell sorting (FACS) was performed at the Flow Cytometry Core Facility of Northwestern University to further select only GFP-positive ADSC or RDF for in vivo experiments.
Preparation of Fibrin Sealant and Harvest of Cells for Topical Delivery to Wounds
Aliquots of the fibrinogen and thrombin components of fibrin sealant (Haemacure Corp., Sarasota, Florida) were prepared at concentrations of 17.3 mg/mL and 167 U/mL, respectively, on the basis of previous work involving fibrin sealant as a delivery vehicle for RDF in rabbit ear wounds. 34 On the day of surgery, ADSC or RDF were trypsinized from 10-cm plates, resuspended in complete media, and counted with the use of a hemacytometer. Sufficient cells were collected for the application of 3 × 10 5 cells (in 30 µL fibrin sealant) to each 6-mm punch wound as previously described. 34 
Ischemic Rabbit Ear Model
Young, female New Zealand White rabbits (three to four months old, 3-4 kg; Covance) were maintained under standard conditions in the Northwestern University Center for Comparative Medicine and managed according to an approved protocol by the institutional Animal Care and Use Committee of Northwestern University. Rabbits were anesthetized with intramuscular ketamine (45 mg/kg) and xylazine (7 mg/kg) on the day of surgery. Ears were shaved, chemically depilated, and prepped with 70% ethanol. Transillumination was performed to mark the caudal, rostral, and central pedicles of the rabbit ear ( Figure  1A ,B). After instillation of local anesthetic (1% lidocaine without epinephrine), an incision was made circumferentially around the base of the ear proximal to the major branch points of the respective pedicles. On the dorsal side, the central artery was dissected free from the central neurovascular bundle under loupe magnification and divided between two suture ties of 5-0 Nylon (Ethicon, Inc., Somerville, New Jersey) ( Figure 1C ). The central nerve was then divided while the vein was left intact. Tissue between the central and caudal pedicles was divided down to the level of bare cartilage with cauterization of the muscle edges performed as needed. The caudal vein was preserved ( Figure 1D ). Attention was then turned to the rostral pedicle, around which a 1-to 2-cm cuff of muscle tissue was left undisturbed so as not to injure the rostral artery, the sole remaining inflow source to the rabbit ear ( Figure 1E ). The incision was closed with a running suture of 5-0 nylon. Sham surgeries were performed by making an identical incision around the ear base and dividing the tissue between the three vascular pedicles down to bare cartilage but leaving the pedicles themselves undissected. Immediately following ischemia surgery, the ventral surface of the rabbit ear was marked for wounding. Six wounds were created per ear in a diamond-shaped fashion around the central axis. Wounds were made with a 6-mm surgical punch biopsy tool (Acuderm, Ft. Lauderdale, Florida) down to, but not through, the cartilage. Pressure was applied so as to create a nick in the cartilage for histologic identification, but not so much as to create a fullthickness defect in the cartilage. Tissue was then elevated in an effort to remove epidermis, dermis, and perichondrium, leaving only the bare cartilage intact. Next, all wounds on a given ear were treated with fibrin sealant vehicle alone, 3 × Figure 1F ). A single 4-0 Prolene suture (Ethicon) was used to tether ears together at the midline to prevent drooping secondary to muscle disruption. Elizabethan collars were applied to prevent self-inflicted trauma to wounds.
Wound Harvesting and Basic Histologic Analysis
On Postoperative Day (POD) 1, 7, or 10, rabbits were anesthetized by intramuscular injection of ketamine (45 mg/ kg) and xylazine (7 mg/kg). Rabbits were then euthanized with the administration of 200 mg/kg intracardiac Euthasol (Virbac AH, Fort Worth, Texas) followed by bilateral thoracotomy. Ears were transected and individual wounds were isolated with a 10-mm surgical punch biopsy tool (Acuderm). Wounds were then bisected and immersed immediately in 10% zinc-formalin. Formalin-fixed wounds were processed, embedded in paraffin blocks, and then sectioned on a microtome at a thickness of 5 µm. Sections were dried on glass slides and then stained with hematoxylin and eosin (H&E) according to standard protocols. Slide images were digitized from a Nikon Eclipse 50i light microscope and subsequently analyzed using NIS Elements BR software (Nikon, Melville, New York) for the PC. Epithelial gap was defined as the one-dimensional distance between the encroaching epithelial edges of the two sides on cross section, whereas the granulation tissue gap was defined as the distance between the new granulation tissue on either side. Values were normalized for a nick-to-nick distance of 6 mm ("corrected gap"). Epithelial and granulation tissue areas were quantified two-dimensionally by encircling the respective areas on the digitized fields ( Figure 3A ). Slides were analyzed and scored in a blinded fashion. Any wounds with gross and/ or histologic evidence of dessication, contamination, physical trauma, or severe inflammation were excluded from the analysis. Results were tabulated using Microsoft Excel (Microsoft, Redmond, Washington). To minimize the effects of rabbit-to-rabbit variation in wound healing, treatments were always formally compared between ears on the same animal. Statistical analyses were made by paired t test with a significance level of P < .05.
Immunoperoxidase and Immunofluorescent Staining
Sections on glass slides were deparaffinized, rehydrated, and incubated in antigen retrieval solution (Dako; Carpinteria, California) for 20 minutes in a food steamer. For immunoperoxidase staining, slides were then washed in PBS, incubated for 15 minutes in a 1% hydrogen peroxide solution, washed again, and then incubated overnight in primary antibody at 4°C. Primary antibody (1:500 anti-GFP chicken IgY; Invitrogen) was diluted in a solution of PBS with 0.3% Triton X-100. With washes in between steps, slides were then incubated sequentially in biotinylated secondary antibody for 1.5 hours (1:200 antichicken; Vector Laboratories, Inc., Burlingame, California), ABC reagent for one hour (Vector Laboratories, Inc.), and a solution of 3,3′-diaminobenzidine tetrahydrochloride (DAB) reagent (Sigma-Aldrich, St. Louis, Missouri) for five to 10 minutes. Dehydrated slides were mounted with Permount (Sigma-Aldrich) and analyzed as described above.
For immunofluorescence, antigen-retrieved slides were washed, permeabilized with PBS containing 0.3% Triton X-100 for five minutes, blocked in 10% normal goat serum for 10 minutes, and then incubated overnight in primary antibody at 4°C. Primary antibody (1:250 anti-GFP chicken IgY [Invitrogen] and 1:50 anti-Ki-67 mouse monoclonal [Leica Microsystems, Inc., Buffalo Grove, Illinois]) was diluted in a solution of PBS with 0.3% Triton X-100 containing 2% normal goat serum. With washes in between steps, slides were then incubated sequentially in secondary antibody for one hour (1:200 Alexa 488 anti-chicken and 1:200 Alexa 594 anti-mouse; Invitrogen), followed by PBS with 0.3% Triton X-100 containing 1 µg/mL 4′,6-diamidino-2-phenylindole (DAPI) for 15 minutes. Slides were then mounted with an aqueous mounting reagent and analyzed on a Zeiss Axiovert widefield fluorescent microscope using AxioVision software (Carl Zeiss AG, Oberkochen, Germany).
Results

Ischemia Significantly Impairs Wound Healing in the Rabbit Ear
As stated earlier, local tissue hypoxia constitutes a major pathophysiologic factor in human chronic wounds. 31, 35 In the early 1990s, our laboratory developed and refined an ischemic variant of the rabbit ear model in which to study the effects of hypoxia on wound healing. 32 As originally reported, the model involved surgical ligation of the central and rostral arteries and left the caudal artery as the sole intact source of inflow to the ear. We have recently modified and simplified the dissection to leave the rostral, rather than the caudal, artery intact as the sole supply to the ear (Figure 1 ). Because the dominant central artery is still ligated with this modification, blood flow to the entire ear remains significantly impaired. The advantages of the current modification relate to the rostral tendon that lies adjacent to the rostral vascular pedicle; with the current method, the rostral tendon need not be dissected out since it is left undisturbed within the muscle cuff surrounding the vascular pedicle. This also minimizes the chance for injury to the tendon, which can result in postoperative drooping of the ear and associated venous congestion.
In the first series of experiments, our objective was to validate the ischemic model with the modification described above and with all ear wounds treated with fibrin sealant vehicle. Because fibrin sealant was to be used to deliver all cell treatments in subsequent analyses, it was necessary to rule out any confounding effects of fibrin sealant on wound healing in this model. In each rabbit, one ear was rendered ischemic while the contralateral ear was subjected to a "sham" surgery in which tissue between the vascular pedicles was divided down to cartilage but the pedicles themselves were left undissected. As could be seen in gross photographs taken of the wounds at the time of harvest on POD 7, sham wounds showed evidence of partial closure from the periphery, whereas ischemic wounds continued to show sharp, "freshly cut" edges with no evidence of healing (data not shown). Histologically, sham wounds demonstrated the presence of new granulation tissue at the edges of the wound as well as migration of the overlying epithelial layer across the wound (Figure 2A) . Epithelialization was complete (ie, epithelial gap = 0 mm) in seven out of 11 wounds (64%). These findings were in marked contrast to those in ischemic wounds, in which granulation tissue was virtually absent ( Figure 2B ). Epithelialization was also affected by ischemia, in that keratinocyte migration was less often complete (two of 12 wounds, or 17%). By POD 10, epithelialization had largely recovered in ischemic wounds, but granulation tissue was still notably deficient ( Figure 2C,D) .
Histologic differences were quantified by digitization of microscope slide images and measurement of epithelial and granulation tissue gaps and areas ( Figure 3A) . As illustrated in Figure 3B , ischemic wounds at POD 7 showed a significant increase in both the mean epithelial , P = .5, n = six), area ( Figure 3E ). Taken together, the above results are consistent with our findings from earlier work 32, 36 that ischemia significantly impairs wound healing. Although epithelialization appears to recover by POD 10 in ischemic wounds owing to a restoration of oxygen tension via collateralization, 36 granulation remains significantly delayed. As evidenced by sham wound healing, the above results also indicate that fibrin sealant does not interfere with wound healing in this model and is therefore an appropriate vehicle for testing cell therapies in this context. Fibrin sealant appears to support cellular migration, as keratinocytes in particular were seen to extend over and through layers of partially degraded fibrin material (data not shown).
ADSC and RDF Remain Suspended in Fibrin Sealant at POD 1 and Express Proliferative Marker Ki-67
To study the potential therapeutic effects of ADSC relative to RDF, both right and left rabbit ears were rendered ischemic and side-by-side comparisons of wound-healing parameters were performed at different time points after treatment, beginning with POD 1. Prior to wound application, ADSC and RDF were transduced with lentivirus to enable the expression of GFP for tracking purposes. In all wounds, cells were seen at POD 1 to be rounded in appearance and distributed relatively evenly across the wound bed in a layer of fibrin matrix ( Figure 4A,C 
,E,G).
No significant qualitative differences were observed between wounds treated with ADSC versus those treated with RDF (n = 12 paired wounds). Immunoperoxidase 
ADSC and RDF Contribute Equivalently to the Accumulation of Neogranulation Tissue Across the Ischemic Wound Bed at POD 7
A similar histologic analysis of the effects of topically delivered ADSC and RDF was performed at POD 7. At this time point, peripheral granulation tissue plugs could be seen qualitatively in H&E-stained sections of both ADSC-and RDF-treated wounds ( Figure 6A,E) . Interestingly, a stratified layer of new granulation tissue could also be seen across the wound bed itself ( Figure 6C,G) . This "neogranulation" tissue was observed in both ADSC-and RDF-treated wounds and appeared to be composed completely of exogenous cells ( Figure 6B,D,F,H) . A similar fibroblastic character to the neogranulation tissue was seen for both cell types, with the layered appearance indicative of cellular proliferation within the wound bed. Interestingly, GFP and Ki-67 double labeling showed the exogenous cells to be negative for the proliferation marker at this time point (Figure 7) , suggesting that the cells reach a steady-state number by POD 7 following an initial period of rapid proliferation within the wound.
Quantitatively, treatment with both ADSC and RDF substantially increased the mean granulation tissue area within the wound (ADSC: 9.2 ± 0.85 × 10 5 vs RDF: 10 ± 1.1 × 10 5 µm 2 , P = .2 for comparison, n = 17 paired wounds; Figure 9B ) relative to POD 7 ischemic controls (0.10 ± 0.064 × 10 5 µm 2 ; Figure 3C ). Moreover, by virtue of accumulation of neogranulation across the entire wound bed, cell treatment reduced the mean granulation tissue gap to nearly zero in ADSC-and RDF-treated wounds Figure 9A ). Notably, neither ADSC nor RDF improved epithelialization of ischemic wounds at POD 7 ( Figure 9A ,B compared with Figure 3B ,C).
Similar Effects of ADSC and RDF at POD 10
Ischemic rabbit ears treated with ADSC or RDF were also analyzed at POD 10 to further track the fate of the topically delivered cells and their effects on wound histology. At this later time point, neogranulation was again observed across the wound bed of both ADSC-and RDF-treated wounds ( Figure 8A,C,E,G) . Immunohistochemical staining against GFP showed this neogranulation to consist of the exogenously applied cells ( Figure 8B,D,F,H) , which were Ki-67 negative by double immunofluorescent labeling techniques just as they were for POD 7 (data not shown). The mean granulation tissue area was again increased (ADSC: 5.8 ± 0.82 × 10 5 vs RDF: 7.0 ± 0.98 × 10 5 µm 2 , P = .3 for comparison, n = nine paired wounds; Figure 9D ), and the mean granulation tissue gap decreased to near zero (ADSC: 0.0 ± 0.0 vs RDF: 0.37 ± 0.37 mm, P = .3 for comparison, n = nine; Figure 9C ) for ADSCand RDF-treated wounds relative to corresponding POD 10 ischemic controls (4.9 ± 1.4 × 10 5 µm 2 and 3.7 ± 0.63 mm, respectively; Figure 3D ,E). As for POD 7, treatment with neither ADSC nor RDF resulted in an improvement of the epithelialization defect caused by ischemia. Informally comparing to ischemic control wounds at POD 10 ( Figure  3D ,E), it appears that the application of both ADSC and RDF contributed negatively to reepithelialization ( Figure  9C,D) . This effect, observed in part at POD 7 but more clearly at POD 10, stands in sharp contrast to the positive effects of exogenous cell delivery on granulation tissue accumulation. 
disCussiOn
Chronic wounds pose a significant health problem in the United States and around the world. It is estimated that the United States alone spends approximately $25 billion annually on chronic wound care, which continues to place a heavy burden on the healthcare system. 37 A recent analysis 37 indicates a much higher-than-expected mortality rate for patients with chronic wounds, on the order of 25% to 30%. Comorbidities such as cardiovascular disease, diabetes mellitus, and peripheral arterial disease are much more prevalent in patients with chronic wounds relative to the general population. Most patients are elderly as well, with a mean age of 75 years. The prevalence of these conditions and their associated predispositions toward states of tissue ischemia, ischemia-reperfusion, bacterial colonization, and cellular changes of aging serve to bolster the unifying hypothesis that these four factors form the basis for the pathogenesis of chronic wounds. 31, 35 These wounds, which are generally seen as diabetic ulcers, venous stasis ulcers, or pressure ulcers, are often refractory not only to conventional therapies but to treatment with newly available bioengineered skin substitutes as well. 16 Over the past 20 years, our laboratory has cultivated a robust wound-healing model in the rabbit ear that allows qualitative and quantitative analysis. We had previously shown that ischemia could be induced in the rabbit ear by ligation of the central, dominant artery, as well as one of the two remaining minor arteries, leaving the third minor artery as the sole source of inflow to the ear. 32 In the current study, we used a slight variation of our previously described model and were able to reconfirm our previous findings of markedly impaired epithelialization and granulation at POD 7. By POD 10, we noted recovery of epithelialization in ischemic wounds as well as a partial recovery of granulation, but healing was still retarded relative to sham controls. The eventual recovery of wound healing in our ischemic model was very likely due to the development of collateral flow by POD 10, as a Doppler signal over the central territory was again audible at this point and the ears were visibly more pink in color (data not shown). This is consistent with our prior analyses of oxygen tension in the ischemic rabbit ear by mixed venous blood gas recording, which showed >75% recovery at POD 10. 36 Given the magnitude of the healthcare burden posed by chronic wounds, the failure of healing in many patients with the use of conventional therapies alone, and the development of a reliable animal model incorporating the physiology seen in chronic human wounds, we sought to evaluate the potential role of ADSC as a novel therapeutic in the ischemic rabbit ear. In so doing, we aimed to compare ADSC with dermal fibroblasts derived from rabbit (RDF) as a control, since fibroblasts already serve as a component of many bioengineered wound dressing systems and are likewise of mesenchymal origin. It was our hope that this analysis would serve as a platform for future investigations into the use of ADSC for other antiscarring and aesthetic applications as has been proposed recently in the clinical arena.
In our experiments, GFP-expressing ADSC and RDF were delivered topically to 6-mm punch wounds on the ischemic rabbit ear in a fibrin sealant matrix. We showed in sham controls that this fibrin sealant matrix had no interfering effect on basic wound healing and was therefore an appropriate vehicle in which to deliver therapeutic cells. As summarized in recent reviews, topical delivery of ADSC or MSC to wounds is one method among several that have been reported, with the others consisting of local or systemic injection of cells. 9, 38 Due to the ease of topical cell application, the lack of invasiveness, and the clinical availability of aerosolized carriers as has been described for cultured epithelial autograft, 13, 14 we believe this method is likely to have greater translational impact. It is important to note that variable rates of ADSC or MSC engraftment in cutaneous wounds have been reported in the literature to date, and the effect of different delivery protocols on these rates is currently not well established. In general, however, rates of exogenous cell engraftment with topical delivery or direct injection into wound sites have been low by both qualitative and quantitative measures. 9, 38 Qualitatively, labeled cells have typically been observed only sparsely throughout the wound bed at seven days and not in a confluent, stratified layer of new tissue as we observed. Quantitative analysis of engraftment (eg, by biochemical dissociation of wounded tissue and FACS analysis of labeled cells) has revealed rates on the order of 10% to 30%. 38 Although we did not perform such a quantitative analysis in our experiments, it is clear from our time course analysis that engraftment rates were significantly higher and that cells even proliferated within the wound bed to reach a steady state. The unprecedented engraftment and proliferation in our experiments may relate to the ischemic background and the activation of cells under hypoxic conditions toward more regenerative functions. Consistent with this hypothesis, ADSC have been shown to have upregulated expression of proangiogenic factors and enhanced capacity for migration and proliferation under conditions of hypoxia in both in vitro and in vivo studies. 30, 39 To our surprise, ADSC and RDF behaved similarly in ischemic rabbit ear wounds from both a qualitative and quantitative standpoint. The application of both cell types resulted in a substantial increase of overall granulation tissue and a granulation tissue gap of zero in almost all wounds due to accumulation of a complete "neogranulation" layer across the entire wound bed. Two explanations may account for our observations: (1) ADSC and RDF behaved similarly because of impurities in the respective cultures, and (2) ADSC and RDF behaved similarly because they truly have similar properties, both in terms of differentiation and/or signaling potential.
With regard to the first possibility, it is well known that in the mesenchymal system, unlike the hematopoietic system, true markers for stem cells remain elusive. 40 Although minimal consensus criteria have been defined for MSC in terms of plastic adherence and expression of antigens such as CD73, CD90, and CD105, 41 it is clear from numerous in vitro studies that fibroblasts have similar morphologic and antigenic characteristics. [42] [43] [44] [45] [46] [47] [48] Several authors have remarked on the fact that fibroblasts, by virtue of their abundance in all connective tissues, are likely to be a contaminant of most primary ADSC/MSC preparations and that it may be impossible to distinguish the two cell types. 43, [46] [47] [48] Conversely, MSC in the form of dermal stem cells may contaminate primary fibroblast cultures. 45 This follows from recent work supporting the view that endogenous MSC are ubiquitously present as pericytes.
1,2 For our analyses, ADSC were isolated from rabbit adipose tissue according to a typical protocol that, like others in common usage, 33 cannot exclude the possibility of contaminant fibroblasts in the preparation. We were, however, able to address the converse problem in our study by using an RDF cell line as our control rather than primary dermal fibroblast cultures. These RDF were noted to be a homogeneous population of spindle-shaped cells and had been passaged numerous times before application to rabbit ear wounds. Based on the low likelihood of contaminating MSC in this cell line, we believe the equivalence in outcomes among ADSC-and RDF-treated wounds in our study reflects true similarity in cellular properties. Numerous recent reports confirming the multipotent differentiation capacity of dermal fibroblasts support this conclusion. 42, 43, [45] [46] [47] Although some groups have been able to discern differences between MSC and dermal fibroblasts in terms of efficiency of differentiation, gene expression profiles during differentiation, or cytokine profile expression in culture in response to various stimuli, 42, 43, 46 very few have rigorously compared ADSC or MSC with dermal fibroblasts in terms of in vivo function. In one recent analysis of ADSC injection therapy for aging skin in mice, fibroblast control injections were noted to produce a statistically-similar increase in dermal collagen density. 49 The equivalence of ADSC and RDF in our study of ischemic wound healing raises the important translational question of what significance these findings may have in terms of therapeutics for human wounds. As noted previously, ADSC can be harvested in abundant amounts from human adipose tissue via simple lipoaspiration techniques. Dermal fibroblast isolation, on the other hand, would require skin harvest. Both procedures could be performed with minimal invasiveness and morbidity, although lipoaspiration would likely be favored due to the potential aesthetic benefit. It is interesting to note that commercial efforts are currently under way for the optimization of both ADSC and fibroblast autologous harvests from human patients.
At POD 7 and POD 10, neither ADSC nor RDF were found to improve the epithelial defects associated with ischemia in our rabbit ear model. RDF performed slightly better than ADSC in terms of epithelial outgrowth at POD 7, but no differences were seen at POD 10. Compared with the rate of reepithelialization of untreated ischemic wounds by POD 10, it appears that the application of both cell types negatively influenced epithelial regrowth. It should be noted, however, that since comparisons in our model are only formally made between ears of the same rabbit (ie, paired experiments) and not across rabbits due to interindividual variation, this conclusion cannot be made with statistical significance. Nonetheless, the trend at least indicates a lack of epithelial recovery with the application of ADSC or RDF that stands in contrast to the markedly positive effect of these cells on granulation. Paracrine signaling from the exogenous cells on adjacent keratinocytes may explain the delay in epithelialization, but the nature of such signals remains unknown. Our results would seem to differ from those of Volk et al, 28 who observed that conditioned media from MSC promoted keratinocyte outgrowth from rabbit skin explants.
The discrepant finding with regard to epithelialization raises the issue of whether an open wound with a reconstituted dermal bed is superior to a closed wound with no underlying dermal support. Currently available therapies such as cultured epithelial autograft (eg, for deep burns) 13, 14 allow wound cover without reconstitution of the underlying bed. As stated earlier, such a strategy is advantageous in the short term, but lack of a support bed for the wound over the long term is not likely to offer a durable solution. Along similar lines, we believe that a "neodermal" bed provided by cellular wound therapy is more critical than simple epithelial cover. Stated differently, the benefits of ADSC or dermal fibroblast therapy in terms of dermal support would seem to outweigh any drawbacks relating to delayed epithelialization. We believe epithelialization is delayed, and not blocked, since we did observe complete epithelialization in wounds analyzed beyond POD 28 (data not shown).
It is important to acknowledge that, in any preclinical study, including our own, the use of allogeneic cells is a key limitation, as any negative effects observed (eg, the lack of epithelialization discussed above) could be attributed to inflammatory changes associated with immune recognition of the transplanted cells. The concern is mitigated, however, by recent comparative analyses in rodents showing that allogeneic and syngeneic MSC engraft similarly in wounds and that the introduction of allogeneic cells is not associated with an increase in the number of overall leukocytes or T lymphocytes within the treated tissue. 50 MSC/ADSC have been described as having immunomodulatory or even immunoinhibitory properties. This has formed the basis for several clinical trials involving infusion of these cells for the treatment of autoimmune diseases. 51 Given the genetic similarity of New Zealand White rabbits as well as the reported lack of antigenicity of MSC/ADSC, we do not believe this to be a significant factor in the outcomes we observed. On the contrary, the equivalence of ADSC and RDF in terms of promoting granulation in our study is all the more striking since immune privilege is not a characteristic that has been observed for allogeneic fibroblasts. 50 One might have predicted a differential response in which RDF showed lack of engraftment secondary to immune rejection, but such a difference was not seen.
COnClusiOns
Cellular therapy with MSC, and ADSC in particular, has garnered tremendous attention in the plastic surgery community and medical field at large. The age of cellular wound therapy is certainly upon us, and MSC/ADSC hold much promise as agents for context-dependent, bioactive wound repair as well as agents for modulation of scarring, regeneration, and rejuvenation. However, as evidenced from our analyses in the rabbit, we are only beginning to understand the complexity of these cells and their mesenchymal stromal counterparts, including dermal fibroblasts. To ensure the safety of our patients and the optimization of results, thorough scientific analysis and in vivo testing are needed before clinical translation.
